title: Portal vein thrombosis after splenectomy for gastric malignant lymphoma.
abstract: Portal vein thrombosis (PVT) has rarely been documented in patients after splenectomy for gastric malignancy. We report a case of PVT that occurred after splenectomy as part of an en-bloc node dissection performed to treat gastric malignant lymphoma. A 38-year-old man underwent total gastrectomy and splenectomy with en-bloc D2 lymph node dissection. The spleen weighed 480 g. On postoperative day (POD) 31, the patient complained of abdominal pain in the right upper quadrant accompanied by fever. Moderate elevations of C-reactive protein (CRP), aspartate transaminase (AST), and alanine transaminase (ALT) were noted. Contrast-enhanced computed tomography (CT) and ultrasonography disclosed thrombus in the portal vein and the splenic vein. There were no abnormalities in the levels of lupus anticoagulant, protein C antigen, protein S antigen, or antithrombin III (AT III). A diagnosis of PVT was made, and prompt treatment, including intravenous heparin combined with tissue plasminogen activator (tPA) was initiated, followed by longterm warfarin. This treatment resulted in clinical improvement, but failed to achieve thrombolysis in the portal vein. At follow-up after 6 months, the patient complained of postprandial abdominal pain with persistent peripheral edema and ascites. This case indicates that splenectomy for en-bloc node dissection in gastric malignancy is a possible cause of PVT. Because both the symptoms and the laboratory data in PVT are nonspecific, a high level of clinical suspicion and a low threshold for obtaining imaging examinations are important in the early diagnosis of PVT. Surgeons should remember PVT among several other complications whenever patients treated with radical gastrectomies are symptomatic and imaging studies are considered necessary.
authors.affiliation: Department of Surgery, Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, 540-0006, Osaka, Japan.
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Fujitani
authors.forename: Akiko
authors.initials: A
authors.lastname: Nishiyama
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Tsujinaka
authors.forename: Motohiro
authors.initials: M
authors.lastname: Hirao
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Hasuike
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
mesh_terms: D000328:Adult; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008223:Lymphoma / Q000601:surgery*; D008297:Male; D011169:Portal Vein / Q000473:pathology*; D011183:Postoperative Complications; D013156:Splenectomy / Q000009:adverse effects*; D013274:Stomach Neoplasms / Q000601:surgery*; D020246:Venous Thrombosis / Q000209:etiology*
chemical_list: D005343:Fibrinolytic Agents